13:@0.490344:0.961646:0.507143:0.961646:0.507143:0.945381:0.490344:0.945381:0.008399:0.008399
百靈佳殷格翰:@0.449093:0.047478:0.549886:0.047478:0.549886:0.035100:0.449093:0.035100:0.016799:0.016799:0.016799:0.016799:0.016799:0.016799
!:@0.891899:0.642626:0.899249:0.642626:0.899249:0.631795:0.891899:0.631795:0.007350
!:@0.884153:0.704535:0.891502:0.704535:0.891502:0.693705:0.884153:0.693705:0.007350
!:@0.913345:0.828354:0.920695:0.828354:0.920695:0.817523:0.913345:0.817523:0.007350
!:@0.906760:0.843832:0.914109:0.843832:0.914109:0.833001:0.906760:0.833001:0.007350
!:@0.895574:0.859309:0.902923:0.859309:0.902923:0.848478:0.895574:0.848478:0.007350
!:@0.893148:0.874786:0.900498:0.874786:0.900498:0.863955:0.893148:0.863955:0.007350
!:@0.306681:0.907604:0.312561:0.907604:0.312561:0.898939:0.306681:0.898939:0.005880
!:@0.627265:0.113925:0.634615:0.113925:0.634615:0.103094:0.627265:0.103094:0.007350
!:@0.587401:0.378740:0.594751:0.378740:0.594751:0.367909:0.587401:0.367909:0.007350
!:@0.577524:0.521091:0.584873:0.521091:0.584873:0.510260:0.577524:0.510260:0.007350
百靈佳殷格翰的研究發展:@0.404093:0.104342:0.625839:0.104342:0.625839:0.089489:0.404093:0.089489:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
自:@0.504886:0.130337:0.525045:0.130337:0.525045:0.115483:0.504886:0.115483:0.020159
1885:@0.427411:0.188431:0.539493:0.188431:0.539493:0.147149:0.427411:0.147149:0.028021:0.028021:0.028021:0.028021
年:@0.552143:0.178628:0.602540:0.178628:0.602540:0.141494:0.552143:0.141494:0.050397
以來百靈佳殷格翰一直致力:@0.394013:0.200892:0.635918:0.200892:0.635918:0.186038:0.394013:0.186038:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
於研究發展:@0.464569:0.223173:0.565362:0.223173:0.565362:0.208319:0.464569:0.208319:0.020159:0.020159:0.020159:0.020159:0.020159
3.1:@0.479936:0.303548:0.549988:0.303548:0.549988:0.262266:0.479936:0.262266:0.028021:0.014010:0.028021
億歐元:@0.484728:0.316009:0.545204:0.316009:0.545204:0.301155:0.484728:0.301155:0.020159:0.020159:0.020159
2016 年研發支出:@0.441890:0.338290:0.588041:0.338290:0.588041:0.323436:0.441890:0.323436:0.010079:0.010079:0.010079:0.010079:0.005040:0.020159:0.020159:0.020159:0.020159:0.020159
8,055:@0.451908:0.418665:0.578001:0.418665:0.578001:0.377383:0.451908:0.377383:0.028021:0.014010:0.028021:0.028021:0.028021
人:@0.504886:0.431126:0.525045:0.431126:0.525045:0.416272:0.504886:0.416272:0.020159
2016 年研究發展部:@0.431811:0.453407:0.598120:0.453407:0.598120:0.438553:0.431811:0.438553:0.010079:0.010079:0.010079:0.010079:0.005040:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
工作人數:@0.474648:0.475687:0.555283:0.475687:0.555283:0.460834:0.474648:0.460834:0.020159:0.020159:0.020159:0.020159
營機構的合作關係，例如結構基:@0.071429:0.109244:0.357185:0.109244:0.357185:0.095628:0.071429:0.095628:0.020733:0.020733:0.020733:0.020733:0.020733:0.020733:0.020733:0.018479:0.020733:0.020733:0.020733:0.020733:0.020733:0.018479
因 組 聯 盟（Structural  Genomics :@0.071429:0.132146:0.366382:0.132146:0.366382:0.118530:0.071429:0.118530:0.018479:0.004908:0.018479:0.004906:0.018479:0.004908:0.018479:0.018479:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.003049:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239
Consortium），並且透過群眾外包:@0.071429:0.155048:0.357143:0.155048:0.357143:0.141432:0.071429:0.141432:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.018479:0.019545:0.019545:0.019545:0.019547:0.019545:0.019545:0.019545:0.019545:0.018479
專案（crowdsourcing）方式為最棘:@0.071429:0.177950:0.357143:0.177950:0.357143:0.164334:0.071429:0.164334:0.018479:0.018126:0.018479:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.018124:0.018479:0.018479:0.018479:0.018479:0.018479
手的醫療問題尋找解決方案。「這:@0.071429:0.200852:0.357143:0.200852:0.357143:0.187236:0.071429:0.187236:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.018479:0.018479:0.019190:0.018479
個方式可以讓我們密切注意仍處於:@0.071429:0.223754:0.357148:0.223754:0.357148:0.210138:0.071429:0.210138:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.018479
初期概念階段的話題，等到時機成:@0.071429:0.246656:0.357167:0.246656:0.357167:0.233040:0.071429:0.233040:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
熟時，我們就會全力投入。」:@0.071429:0.269558:0.311653:0.269558:0.311653:0.255942:0.071429:0.255942:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
    免疫調節即是百靈佳殷格翰使:@0.071429:0.292460:0.357143:0.292460:0.357143:0.278844:0.071429:0.278844:0.011372:0.011374:0.011372:0.011372:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
用科學平臺途徑的一個例子。「在:@0.071429:0.315363:0.357143:0.315363:0.357143:0.301747:0.071429:0.301747:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.018479:0.018479:0.019190:0.018479
廣泛的醫療領域中，免疫系統是許:@0.071429:0.338265:0.357167:0.338265:0.357167:0.324649:0.071429:0.324649:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.018479:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
多疾病的共同點。」伍德說明。以:@0.071429:0.361167:0.357148:0.361167:0.357148:0.347551:0.071429:0.347551:0.019255:0.019255:0.019255:0.019255:0.019255:0.019255:0.018479:0.018479:0.019255:0.019255:0.019255:0.019255:0.018479:0.019255:0.018479
前公司必須聘雇所有相關治療領域:@0.071429:0.384069:0.357148:0.384069:0.357148:0.370453:0.071429:0.370453:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.018479
小組的免疫學家。「現在則是把他:@0.071429:0.406971:0.357143:0.406971:0.357143:0.393355:0.071429:0.393355:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.018479:0.018479:0.019190:0.019190:0.019190:0.019188:0.019190:0.019190:0.018479
們全部聚集在一個平臺即可。」目:@0.071429:0.429873:0.357143:0.429873:0.357143:0.416257:0.071429:0.416257:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.019190:0.019190:0.019188:0.019190:0.018479:0.018479:0.019190:0.018479
前約有兩百位專家著手研究，希望:@0.071429:0.452775:0.357167:0.452775:0.357167:0.439159:0.071429:0.439159:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.018479
找出影響免疫系統新的可能性。一:@0.071429:0.475677:0.357159:0.475677:0.357159:0.462061:0.071429:0.462061:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.018481:0.019135:0.018479
個疾病（如自體免疫疾病，亦即免:@0.071429:0.498579:0.357143:0.498579:0.357143:0.484963:0.071429:0.484963:0.019190:0.019188:0.018481:0.019188:0.019190:0.019190:0.019188:0.019190:0.019190:0.019190:0.018479:0.019188:0.019190:0.019190:0.018479
疫系統過度活化）必須關閉的免疫:@0.071429:0.521481:0.357148:0.521481:0.357148:0.507865:0.071429:0.507865:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.018479
通道有可能是開啟對抗癌症（免:@0.667611:0.154898:0.928532:0.154898:0.928532:0.141282:0.667611:0.141282:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018479
疫系統可能啟動不足）的通道。:@0.667611:0.177800:0.928532:0.177800:0.928532:0.164184:0.667611:0.164184:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018479
科學家一起研究這些共同的問:@0.667611:0.200702:0.928565:0.200702:0.928565:0.187086:0.667611:0.187086:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.018479
題，創造出巨大的價值，與各自:@0.667611:0.223604:0.928550:0.223604:0.928550:0.209988:0.667611:0.209988:0.018479:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479:0.018682:0.018682:0.018682:0.018479
在不同組織單位研究的結果不可:@0.667611:0.246507:0.928476:0.246507:0.928476:0.232891:0.667611:0.232891:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
相提並論。免疫調節和造成纖維:@0.667611:0.269409:0.928532:0.269409:0.928532:0.255793:0.667611:0.255793:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
化的潛在機制，就是百靈佳殷格:@0.667611:0.292311:0.928532:0.292311:0.928532:0.278695:0.667611:0.278695:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
翰目前正在探索的科學平臺途徑:@0.667611:0.315213:0.928476:0.315213:0.928476:0.301597:0.667611:0.301597:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
範例。然而，伍德與同事們已在:@0.667611:0.338115:0.928550:0.338115:0.928550:0.324499:0.667611:0.324499:0.018682:0.018479:0.018682:0.018682:0.018479:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479
討論進一步的研究領域，而再生:@0.667611:0.361017:0.928532:0.361017:0.928532:0.347401:0.667611:0.347401:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018479
醫學就是一個可能性。:@0.667611:0.383919:0.852399:0.383919:0.852399:0.370303:0.667611:0.370303:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
    「研究的開放性與互惠互利:@0.667611:0.406821:0.928563:0.406821:0.928563:0.393205:0.667611:0.393205:0.009801:0.009803:0.009801:0.009801:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
的合作關係，這樣的新文化現:@0.667611:0.429723:0.928569:0.429723:0.928569:0.416107:0.667611:0.416107:0.020364:0.020364:0.020364:0.020364:0.018479:0.020364:0.020364:0.020364:0.020364:0.020364:0.020364:0.020364:0.018479
在引導公司的研發工作。」伍德:@0.667611:0.452625:0.928548:0.452625:0.928548:0.439009:0.667611:0.439009:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018477:0.018479:0.018682:0.018682:0.018479
說。他提到 ofev? 是公司一個出:@0.667611:0.475527:0.928515:0.475527:0.928515:0.461911:0.667611:0.461911:0.018479:0.018738:0.018738:0.018738:0.018479:0.004686:0.009239:0.009239:0.009239:0.009239:0.009239:0.004684:0.018738:0.018738:0.018738:0.018738:0.018738:0.018479
色的範例。這是對業務成長有重:@0.667611:0.498429:0.928532:0.498429:0.928532:0.484813:0.667611:0.484813:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
大貢獻的一支藥品。百靈佳殷格:@0.667611:0.521332:0.928532:0.521332:0.928532:0.507716:0.667611:0.507716:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
翰的腫瘤研究部最初以酪胺酸:@0.667611:0.544234:0.928565:0.544234:0.928565:0.530618:0.667611:0.530618:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.018479
激 ? 抑 制 劑（tyrosine  kinase :@0.667611:0.567136:0.937803:0.567136:0.937803:0.553520:0.667611:0.553520:0.018479:0.005464:0.009239:0.005462:0.018479:0.003376:0.018479:0.003376:0.018479:0.018479:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.003049:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239
inhibitor）nintedanib 研 發 出:@0.667611:0.590038:0.928563:0.590038:0.928563:0.576422:0.667611:0.576422:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.018479:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.005383:0.018479:0.003053:0.018479:0.003053:0.018479
一支療效非常好的肺癌藥。「後:@0.667611:0.612940:0.928550:0.612940:0.928550:0.599324:0.667611:0.599324:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479:0.018479:0.018682:0.018479
來我們在德國比伯拉赫的兩位傑:@0.667611:0.635842:0.928476:0.635842:0.928476:0.622226:0.667611:0.622226:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
出科學家突然想到發生癌症的:@0.667611:0.658744:0.928565:0.658744:0.928565:0.645128:0.667611:0.645128:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.020205:0.020207:0.020207:0.020207:0.020207:0.018479
機轉或可有效治療特發性肺纖維:@0.667611:0.681646:0.928476:0.681646:0.928476:0.668030:0.667611:0.668030:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
化。」他說。「而這當然就意味:@0.667611:0.704548:0.928569:0.704548:0.928569:0.690932:0.667611:0.690932:0.018479:0.018479:0.018728:0.018728:0.018479:0.018479:0.018728:0.018728:0.018728:0.018728:0.018738:0.018728:0.018728:0.018479
著 nintedanib 的活性成分可以:@0.667611:0.727450:0.928563:0.727450:0.928563:0.713834:0.667611:0.713834:0.018479:0.005061:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.005061:0.020247:0.020245:0.020247:0.020245:0.020245:0.020247:0.018479
用於治療這個疾病。」他們在一:@0.667611:0.750352:0.928550:0.750352:0.928550:0.736736:0.667611:0.736736:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479:0.018479:0.018682:0.018682:0.018682:0.018682:0.018479
系列的實驗中證明這個潛力，於:@0.667611:0.773254:0.928532:0.773254:0.928532:0.759639:0.667611:0.759639:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018479
是成功的主張針對這個適應症對:@0.667611:0.796157:0.928476:0.796157:0.928476:0.782541:0.667611:0.782541:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
nintedanib 進 行 試 驗。「 常 見:@0.667611:0.819059:0.928563:0.819059:0.928563:0.805443:0.667611:0.805443:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.005387:0.018479:0.003069:0.018479:0.003067:0.018479:0.003067:0.018479:0.018479:0.018479:0.003069:0.018479:0.003067:0.018479
疾病機轉的重要性已經反覆被證:@0.667611:0.841961:0.928476:0.841961:0.928476:0.828345:0.667611:0.828345:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
明。開放的心態與協助病患的目:@0.667611:0.864863:0.928532:0.864863:0.928532:0.851247:0.667611:0.851247:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
標是發明藥物的核心。」:@0.667611:0.887765:0.870878:0.887765:0.870878:0.874149:0.667611:0.874149:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479